Heat-activated thermosensitive liposomal cisplatin (HTLC) results in effective growth delay of cervical carcinoma in mice

Dou, Yannan N.; Zheng, Jinzi; Foltz, Warren D.; Weersink, Robert A.; Chaudary, Naz; Jaffray, David A.; Allen, Christine

doi:10.1016/j.jconrel.2014.01.009

Cited by 75 publications

(69 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, local hyperthermia triggers intravascular drug release in the heated zone. This mechanism enhances drug delivery to the tumour many fold, increases drug diffusion distance from the vasculature and enhances antitumour activity of several drugs, including doxorubicin, cisplatin and gemcitabine [76][77][78][79][80]. Because of the differential in systemic versus local effects of these formulations, one could administer less than the maximally tolerated dose and still enhance drug delivery to the bladder tumour.…”

Section: Rationale For Intravenous Drug Administration In the Treatmementioning

confidence: 99%

Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer

Heijden

Dewhirst

2016

International Journal of Hyperthermia

View full text Add to dashboard Cite

Non-muscle-invasive bladder cancer is a challenging disease, even given its superficial nature. It is prone to multiple recurrences and progression to muscle-invasive cancer. These features of this disease contribute significantly to reduced quality of life as well as creating significant morbidity and even mortality. Randomised trials demonstrate that when hyperthermia is added to conventional mitomycin-C treatment that local control rates and progression-free survival are substantially improved. In this review we consider how hyperthermia can exert such beneficial effects. Some of the mechanisms presented are theoretical, while others are facts. It is hoped that this review will contribute rationale for further examination of mechanisms, because an understanding of such mechanisms may lead to even better chemotherapeutic approaches, as well as potential biomarkers for predicting and monitoring treatment success.ARTICLE HISTORY

show abstract

Section: Rationale For Intravenous Drug Administration In the Treatmementioning

confidence: 99%

Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer

Heijden

Dewhirst

2016

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

“…The effective release of encapsulated agents from the HTLC liposomes translated into improved efficacy, with the heated HTLC group resulting in a significant therapeutic advantage over other treatment and control groups 16 .…”

Section: Conformal Heating Of Tumor Using Custom-designed Laser Chambmentioning

confidence: 99%

Custom-designed Laser-based Heating Apparatus for Triggered Release of Cisplatin from Thermosensitive Liposomes with Magnetic Resonance Image Guidance

Dou

Weersink

Foltz

et al. 2015

JoVE

Self Cite

View full text Add to dashboard Cite

Liposomes have been employed as drug delivery systems to target solid tumors through exploitation of the enhanced permeability and retention (EPR) effect resulting in significant reductions in systemic toxicity. Nonetheless, insufficient release of encapsulated drug from liposomes has limited their clinical efficacy. Temperature-sensitive liposomes have been engineered to provide site-specific release of drug in order to overcome the problem of limited tumor drug bioavailability. Our lab has designed and developed a heat-activated thermosensitive liposome formulation of cisplatin (CDDP), known as HTLC, to provide triggered release of CDDP at solid tumors. Heat-activated delivery in vivo was achieved in murine models using a custom-built laser-based heating apparatus that provides a conformal heating pattern at the tumor site as confirmed by MR thermometry (MRT). A fiber optic temperature monitoring device was used to measure the temperature in real-time during the entire heating period with online adjustment of heat delivery by alternating the laser power. Drug delivery was optimized under magnetic resonance (MR) image guidance by co-encapsulation of an MR contrast agent (i.e., gadoteridol) along with CDDP into the thermosensitive liposomes as a means to validate the heating protocol and to assess tumor accumulation. The heating protocol consisted of a preheating period of 5 min prior to administration of HTLC and 20 min heating post-injection. This heating protocol resulted in effective release of the encapsulated agents with the highest MR signal change observed in the heated tumor in comparison to the unheated tumor and muscle. This study demonstrated the successful application of the laser-based heating apparatus for preclinical thermosensitive liposome development and the importance of MRguided validation of the heating protocol for optimization of drug delivery. Video LinkThe video component of this article can be found at

show abstract

“…A novel heat-activated thermosensitive liposome formulation containing cisplatin was developed to release around 90% of the loaded drug within 5 min in mild heating conditions. The results indicated that the heat-activated, triggered release formulation of cisplatin can improve the therapeutic index of the drug [44]. Also, doxorubicin liposomes (Lipo-DOX) were developed and studied at a dose of 20 mg/m 2 in formerly treated patients with recurrent cervical cancer as a Simon’s two-stage Phase II clinical trial.…”

Section: Systemic Versus Localized Drug Delivery Systemsmentioning

confidence: 99%

“…No.Drug/antibodyType/composition of liposomesCell lines/animal/clinical modelsReference1.PaclitaxelStearyl amine-based positively charged multilayered liposomesHeLa cell lines[42]2.Cisplatin–ME-180 cervical cancer cell line, cisplatin-resistant clone R-ME-180 and HeLa cells[43]3.CisplatinHeat-activated thermosensitive liposome–[44]4.Doxorubicin–Cervical cancer patients[45]5.IL-2Anionic, cationic, and neutral liposomesINBL cells 6.DoxorubicinTransferrin (Tf)-conjugated stealth liposomes (Tf-SL-DOX)–[47]7.DoxorubicinLiposomes conjugated with folic acid and transferrinHeLa cells[48]8.IL-2Cationic liposome containingINBL cells induced tumor-containing immune-depressed CBA mice[49] …”

Section: Systemic Versus Localized Drug Delivery Systemsmentioning

confidence: 99%

Possible role of nanocarriers in drug delivery against cervical cancer

Gupta

2017

Nano Reviews & Experiments

View full text Add to dashboard Cite

Introduction: Cervical cancer is the second most common cancer and the largest cancer killer among women in most developing countries including India. Although, various drugs have been developed for cervical cancer, treatment with these drugs often results in a number of undesirable side effects, toxicity and multidrug resistance (MDR). Also, the outcomes for cervical cancer patients remain poor after surgery and chemo radiation. Methods: A literature search (for drugs and delivery systems against cervical cancer) was performed on PubMed and through Google. The present review discuss about various methods including its current conventional treatment with special reference to recent advances in delivery systems encapsulating various anticancer drugs and natural plant products for targeting towards cervical cancer. The role of photothermal therapy, gene therapy and radiation therapy against cervical cancer is also discussed. Results: Systemic/targeted drug delivery systems including liposomes, nanoparticles, hydrogels, dendrimers etc. and localized drug delivery systems like cervical patches, films, rings etc. are safer than the conventional chemotherapy which has further been proved by the several drug delivery systems undergoing clinical trials. Conclusion: Novel approaches for the aggressive treatment of cervical cancer will optimistically result in decreased side effects as well as toxicity, frequency of administration of existing drugs, to overcome MDR and to increase the survival rates.

show abstract

Heat-activated thermosensitive liposomal cisplatin (HTLC) results in effective growth delay of cervical carcinoma in mice

Cited by 75 publications

References 41 publications

Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer

Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer

Custom-designed Laser-based Heating Apparatus for Triggered Release of Cisplatin from Thermosensitive Liposomes with Magnetic Resonance Image Guidance

Possible role of nanocarriers in drug delivery against cervical cancer

Contact Info

Product

Resources

About